Kisqali on PBS, very few will get it.
those of us who were waiting to get Ibrance or Kisqali on PBS we will not get either. Only newly the diagnosed who have NOT had an Aromatose drug. ( there would be very few of them ) BCNA failed t...
Forum Discussion
Ribociclib has been approved for listing on the PBS forpeople with metastatic breast cancer under specific conditions. The criteria is for hormone receptor positive, HER2 negative metastic breast cancer as first line treatment for Metastatic disease and is used in combination with an aromatise inhibitor (AI) such as letrazole (Femara). The metastatic breast cancer must not have been treated with an AI. @kmakm based on the details you’ve provided and the current eligibility criteria, you would be eligible for treatment with Ribociclib. As always, your oncologist is best placed to explain each person’s situation and likely benefit or risk of any new treatment. Please refer to the link @Riki_BCNA posted above. https://www.bcna.org.au/news/2018/07/ribociclib-now-on-the-pbs-for-people-newly-diagnosed-with-metastatic-breast-cancer/
BCNA is continuing to advocate for this class of drugs (CDK inhibitors) to be made available to people with metastatic breast cancer who have had additional lines of treatments.
BCNA is continuing to advocate for this class of drugs (CDK inhibitors) to be made available to people with metastatic breast cancer who have had additional lines of treatments.